NBTXR3 (PEP-503) for head and neck squamous cell carcinoma in elderly patients

featured image
Interventions: NBTXR3
Indications: Head and neck cancer
Therapeutic Areas: Head and Neck Cancer
Year: 2017

Squamous cell carcinoma is a cancer that arises from particular cells called squamous cells, a type of skin cell. They are found in the outer layer of skin and in the mucous membranes; the moist tissues that line body cavities such as the airways and intestines. Head and neck squamous cell cancer develops in the mucous tissues of the mouth, nose and throat. Head and neck squamous cell cancer accounted for three percent of all cancers in the United Kingdom in 2014.
NBTXR3 is under development for the treatment of head and neck squamous cell cancer and is currently in phase I/II clinical trials. If effective NBTXR3 will enhance current treatment options. As a first in class treatment designed to penetrate cancer cells and remain within the tumour, increasing the radiation dose in the tumour but not in the surrounding healthy tissue. NBTXR3 is administered as an intra-tumoural or intra-arterial injection.